Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


WHO-Klassifikation maligner Non-Hodgkin-Lymphome: charakteristische immunphänotypische und zytogenetische Veränderungen

Autor/en: M. Uppenkamp
Letzte Änderung: 30.05.2003
Tabelle 5b: B-Zell Lymphome: Immunphänotyp und Zytogenetik
WHO 2001Immunphänotyp (nur positive Expression)Zytogenetische Veränderungen
Precursor B-cell diseases
Precursor B-lymphoblastic lymphoma/ leukemiaDepending on degree of differentiation:
TdT, HLA-DR, CD19, CD10, CD24, CD22, CD20, cCD79a, cCD22, cIgM
  • t(9;22)(q34;q11.2) BCR/ABL
  • t(4;11)(q21;q23) AF4/MLL
  • t(1;19)(q23;p13.3) PBX/E2A
  • t(12;21)(p13;q22) TEL/AML1
  • hypodiploid, hyperdiploid >50
Mature B-cell disease
Chron. lymphocytic leukemia/ small lymphocytic lymphomasIg dim; CD5, CD19, CD20 weak; CD22 weak; CD79a; CD23, CD11c weakdel 6(q21), del11(q22-23), del13(q14), del17(p13); Trisomies 3, 8, 12; abn.14q32, t(11;14)(q13;q32)
Prolymphocytic leukemiasIgM/IgD, CD19, CD20, CD22, CD79a/b, FMC7, CD5 in 1/3 of casesdel 11(q23), del13(q14)
Lymphoplasmacytic lymphoma/
Waldenström macroglobulinemia
cIgM, CD19, CD20, CD22, CD79a, CD38, CD43+/-t(9;14)(p13;q32)
Splenic marginal zone lymphomasIgM/D, CD20, CD79adel 7(q21-32), trisomy +3
Hairy cell leukemiasIg+, CD19, CD20, CD22, CD79a, CD11c, CD25, FMC7, CD103no specific abnormalities
Plasma cell neoplasmscIgG/A/D/E/M, CD38, CD79a, CD56/58, CD138
  • Structural/numeric aberrations: 1; 11; 14
  • gains (3, 5, 7, 9, 11, 15, 19)
  • losses (8, 13, 14, X); 13q14, del 7q, del 17(p13); t(11;14)(q13;q32)
Extranodal marginal zone B-cell lymphoma of MALT typesIgM, κ/λ restriction, CD20, CD79a, CD43+/-, CD11c+/-, CD21, CD35trisomy 3
t(11;18)(q21;q21) API2/MLT
Nodal marginal zone B-cell lymphomaSimilar to extranodal marginal zone lymphomano consistent pattern

Follicular lymphoma,
Variants:

  • grade 1, 2
  • grade 3 a and b
sIg+, BCL2+, CD10, CD19, CD20, CD22, CD79a
  • t(14;18)(q32;q21) IgH/BCL2
  • t(2;18)(p12;q21) IgL/BCL2
  • +7, +18, del6q(23-26), abn. 17p13, 3q27
Mantle cell lymphoma,
Variant: blastic
sIgM, CD5, CD23+/-, FMC7, CD43
  • t(11;14)(q13;q32) IgH/BCL1
  • del 17p, del 13(q14), trisomy +12
  • Diffuse large B-cell lymphoma

CD19, CD20, CD22, CD79a, s/cIg+, CD10+/-, BCL2+/-, Ki67

t(14;18)(q32;q21) IgH/BCL2

 

     Variants:  abn. 3q27 BCL6
centroblastic   
immunoblastic 
T-cell or histiocyte rich 
anaplastic large cell CD30
Mediastinal (thymic) large B-cell lymphomaCD19, CD20, CD30 weak, CD45hyperdiploid
gains 9p
Intravascular large B-cell lymphomaCD19, CD20, CD22, CD79a, CD5+/-no consistent pattern
Primary effusion lymphomaCD45, CD30, CD38, CD138, aberrant CD5no consistent pattern

Burkitt lymphoma (BL)

Variants: BL with plasmacytoid differentiation; atypical Burkitt/Burkitt-like

sIgM, κ/λ restriction, CD19, CD20, CD22, CD10, BCL6+,
EBV+/-
  • t(8;14)(q24;q32) IgH/MYC
  • t(2;8)(q11;q32) Igκ/MYC
  • t(8;22)(q32;q11) Igλ/MYC
Lymphomatoid granulomatosisEBV+, CD20, CD30+/-, CD79a+/-No alterations identified

Zur besseren Vergleichbarkeit wurden die englischen Bezeichnungen beibehalten.

t=Translokation
del=Deletion
abn.=Abnormalitäten
+/- in einigen Fällen positiv
sIg=Oberflächenimmunglobuline
cIg=zytoplasmische Immunglobuline
IgH=Schwerketten-Gen der Immunglobulin
IgL= Leichtketten-Gen der Immunglobuline

Tabelle 6b: T-Zell Lymphome: Immunphänotyp und Zytogenetik
WHO 2001

Immunphänotyp

(nur positive Expression)

Zytogenetische Veränderungen
Precursor T-cell diseases
Precursor T-lymphoblastic lymphoma/ leukemiaTdT, CD1a, CD2, CD3, CD4, CD8, CD13+/-, CD33+/-
  • t14(q11.2) TCRα/δ,
  • t7(q35) TCRβ,
  • t7(p14-15) TCRγ with 8q24.1 MYC,
  • 1p32 TAL-1,
  • 11p15 RBTN1,
  • 11p13 RBTN2,
  • 10q24 HOX11,
  • 1p34-35 LCK
Mature T-cell/ NK-cell disease
Prolymphocytic leukemiaCD2, CD3, CD7, CD4/CD8+/-
  • t14(q11), t14(q32),
  • t(14;14)(q11;q32) TCRα/β/TCL1
  • t(8;8)(p11-12;q12); trisomy 8q;
  • del 12(p13); del 11(q23) ATM
  • t(X;14)(q28;q11) TCRα/β/MTCP1
T-cell large granular lymphocyte leukemiaCD3, TCRα/β, CD4/8+/-, CD11b+/-, CD56+/-, CD57+/-no consistent pattern
Aggressive NK-cell leukemiaCD2, CD3ε, CD56del6(q21q25)
Adult T-cell leukemia/ lymphoma
(HTLV-1+)
CD2, CD3, CD5, CD4/8+/-, CD25no specific abnormalities
Extranodal NK/ T-cell lymphoma, nasal typeCD2, CD56, cCD3ε, CD7+/-, CD30+/-del6(q21q25); i6(p10)
Enteropathy-type T-cell lymphomaCD3, CD7, CD8+/-, CD103, CD30+/-no specific abnormalities
Hepatosplenic T-cell lymphomaCD3, CD56+/-, TCRδ1i7q; trisomy 8
Subcutaneous panniculitis-like T-cell lymphomaCD3, CD8, CD56no specific abnormalities
Blastic NK-cell lymphomaCD56, CD4, CD43no specific abnormalities
Mycosis fungoides and Sézary syndromeCD2, CD3, TCRβ, CD5, CD4no specific abnormalities

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders

  • primary cutaneous anaplastiv large cell lymphoma,
  • lymphomatoid papulosis
CD2, CD3, CD4, CD5, CD30no specific abnormalities
Angioimmunoblastic T-cell lymphomaCD3, CD4, CD8trisomy 3; trisomy 5; +X
  • Peripheral T-cell lymphoma, unspecified
CD3, CD4, CD30+/-no specific abnormalities
     

Variants:

  • lympho-
    epithelioid cell,
  • T-zone lymphoma
 trisomy 3 (lymphoepithelioid cell)
Anaplastic large cell lymphoma,
primary systemic
CD30, ALK, EMA, CD3+/-, CD2, CD4, CD43+/-, CD25
  • t(2;5)(p23;35) ALK/NPM
  • t(1;2)(q25;p23) TPM3/ALK
  • t(2;3)(p23;q35) ALK/TFG
  • inv 2(p23q35) ATIC/ALK
  • t(2;17)(p23;q11) ALK/CLTC

Zur besseren Vergleichbarkeit wurden die englischen Bezeichnungen beibehalten.

t=Translokation
del=Deletion
abn.=Abnormalitäten;
i=Isochromosom
inv=Inversion
+/- in einigen Fällen positiv
TCR=T-Zell Rezeptor Gen

Die Publikation dieser Rubrik wird gefördert durch:
mehr 
[Mehr]
Aktuelle Berichte vom 57th
ASH Annual Meeting 2015,
Orlando, Florida, USA [Mehr]
2015 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]